(Q36689005)

15 August 2017

1 reference

title

Pollinex Quattro: a novel and well-tolerated, ultra short-course allergy vaccine (English)

1 reference

15 August 2017

Piyush Patel

1

1 reference

15 August 2017

Anne Marie F Salapatek

series ordinal

2

1 reference

15 August 2017

publication date

1 October 2006

1 reference

Expert Review of Vaccines

15 August 2017

published in

1 reference

15 August 2017

volume

5

1 reference

15 August 2017

issue

5

1 reference

15 August 2017

page(s)

617-629

1 reference

Allergic rhinitis: impact of the disease and considerations for management

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.617

Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.617

Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.617

Hay fever, hygiene, and household size

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.617

The allergy adjuvant effect of particles - genetic factors influence antibody and cytokine responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.617

Effectiveness of specific immunotherapy in the treatment of allergic rhinitis: an analysis of randomized, prospective, single- or double-blind, placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.617

Immunological mechanisms of specific allergen immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.617

Clinical practice. Allergic rhinitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.617

Modern approaches to therapeutic vaccination as treatment for type 1 respiratory hypersensitivity (allergy) treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.617

Long-term clinical efficacy of grass-pollen immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.617

Review of L-tyrosine confirming its safe human use as an adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.617

Safety evaluation of monophosphoryl lipid A (MPL): an immunostimulatory adjuvant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.617

Taking toll: lipid A mimetics as adjuvants and immunomodulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.617

Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.617

Monophosphoryl lipid A (MPL) promotes allergen-induced immune deviation in favour of Th1 responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.617

A Th1-inducing adjuvant, MPL, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.617

A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.617

Efficacy and tolerability of short-term specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A (MPL) for children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.617

Safety evaluation of a new allergy vaccine containing the adjuvant monophosphoryl lipid A (MPL) for the treatment of grass pollen allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.617

Vaccines for birch pollen allergy based on genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.617

Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.617

21 January 2018

Identifiers

DOI

10.1586/14760584.5.5.617

1 reference

15 August 2017

1 reference